Skip to main content
Premium Trial:

Request an Annual Quote

Generation Health Contracts with PGXL to Offer Pharmacogenetic Tests

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Generation Health has contracted with PGXL Laboratories to be a preferred genetic testing lab providing molecular diagnostic test services for Generation Health.

In a pilot program starting next month, the partners will provide pharmacogenetic testing and diagnostic services to a limited number of patients through healthcare providers. In January 2011, those services will be opened up to all GH patients, Brad Esarey, director of sales and marketing for PGXL, said.

Terms of the agreement were not disclosed.

Based in Louisville, KY., PGXL is a molecular diagnostics lab. According to PGXL, it was the first laboratory in the country specifically CLIA certified to provide pharmacogenetic tests. Generation Health is a genetic benefit management company based in Upper Saddle River, NJ, partially owned by pharmacy services and benefit management firm CVS Caremark.

The Scan

Transplant Tests Edited Pig Kidneys

The Associated Press reports a University of Alabama-Birmingham team transplanted genetically modified pig kidneys into a brain-dead human patient.

UK Changes Some Gene-Edited Crop Rules

A new law may enable gene-edited crops to be sold in the UK within about five years, New Scientist says.

Pill Works Against Omicron in Lab

Pfizer's antiviral pill to treat SARS-CoV-2 appears to work against the Omicron variant, the Wall Street Journal reports.

Nature Papers Find Genetic Risk Factor for Smell, Taste Loss in COVID-19; Analyze TB Granulomas

In Nature this week: genome-wide association study find locus linked to the risk COVID-19 patients losing their sense of taste or smell, and more.